As the year comes to a close, we revisit some of this year’s top content on bladder cancer.
There’s been an abundance of news surrounding bladder cancer over the past year. In light of all that has been discovered, Urology Times® is counting down the top pieces of content surrounding bladder cancer in 2022.
Data presented at the 2022 Genitourinary Cancers Symposium showed encouraging antitumor activity in patients with muscle-invasive bladder cancer (MIBC) who were ineligible for cisplatin receiving treatment with neoadjuvant enfortumab vedotin (Padcev) who were ineligible for cisplatin. Read more.
The findings, derived from Cohort K of the EV-103 trial (NCT03288545), were presented at ESMO Congress 2022 by Jonathan E. Rosenberg, MD. Read more.
Immunotherapy and targeted therapies have revolutionized the treatment paradigm in metastatic urothelial cancer, with more advances to come on the horizon, explained Daniel P. Petrylak, MD, in a discussion at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies. Read more.
Findings from the phase 3 FinnBladder 9 trial published in European Urology Focus suggest that public knowledge of the increased risk of bladder cancer due to smoking is low, highlighting the need to raise awareness through more publicity and education. Read more.
In this video, Janet Kukreja, MD, discusses abstracts on urothelial carcinoma, renal cell carcinoma, and muscle-invasive bladder cancer that were presented at the 2022 Genitourinary Cancers Symposium. Watch now.
Fed Ghali, MD, a urologic oncology fellow at the University of Washington, discusses the outlook for patients with variant histology bladder cancer and how antibody-drug conjugates may provide a new treatment option in this setting. Watch now.
Kyle Rose, MD, urologic oncology fellow at Moffitt Cancer Center, discusses the abstract, “Antegrade Administration of Reverse Thermal Mitomycin Gel for Primary Chemoablation of Upper Tract Urothelial Carcinoma via Percutaneous Nephrostomy Tube: A Multi-Institutional Real-World Experience,” from the 2022 AUA Annual Meeting. Watch now.
Pedro C. Barata, MD, MSc, an associate professor at Tulane University School of Medicine, discusses the importance of tumor sequencing to the implementation of precision medicine for patients with urothelial carcinoma. Watch now.
The Centers for Medicare and Medicaid Services is covering the Signatera molecular residual disease test for use in patients with MIBC, according to Natera, the developer of the assay. Read more.
The initial results from JAVELIN Bladder 100 supported the FDA approval of avelumab for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma. Watch now.